Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SXC-2023 Phase 1 SAD and Food Effect Study
NCT03301298Phase 1Completed
- Sponsor
- Promentis Pharmaceuticals, Inc.
- Start
- Sep 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SXC-2023 in trichotillomania (TTM) and obsessive compulsive disorder (OCD) (7 arms), sponsored by Promentis Pharmaceuticals, Inc. Primary endpoint: Treatment-Emergent Adverse Events at 8 days. Started Sep 2017; status: completed.
02
Drugs
SXC-2023
03
Conditions
trichotillomania (TTM)obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT03301298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03301298.